Modulation of β‐amyloid metabolism by non‐steroidal anti‐inflammatory drugs in neuronal cell cultures
Open accessThe DOI matches its Crossref record; 15 of the 15 references it cites were found in a registry or an index.
Abstract
Alzheimer disease (AD) is characterized by cerebral deposits of β‐amyloid (Aβ) peptides, which are surrounded by neuroinflammatory cells. Epidemiological studies have shown that prolonged use of non‐steroidal anti‐inflammatory drugs (NSAIDs) reduces the risk of developing AD. In addition, biological data indicate that certain NSAIDs specifically lower Aβ42 levels in cultures of peripheral cells independently of cyclooxygenase (COX) activity and reduce cerebral Aβ levels in AD transgenic mice. Whether other NSAIDs, including COX‐selective compounds, modulate Aβ levels in neuronal cells remains unexploited. Here, we investigated the effects of compounds from every chemical class of NSAIDs on Aβ40 and Aβ42 secretion using both Neuro‐2a cells and rat primary cortical neurons. Among non‐selective NSAIDs, flurbiprofen and sulindac sulfide concentration‐dependently reduced the secretion not only of Aβ42 but also of Aβ40. Surprisingly, both COX‐2 (celecoxib; sc‐125) or COX‐1 (sc‐560) selective compounds significantly increased Aβ42 secretion, and either did not alter (sc‐560; sc‐125) or reduced (celecoxib) Aβ40 levels. The levels of βAPP C‐terminal fragments and Notch cleavage were not altered by any of the NSAIDs, indicating that γ‐secretase activity was not overall changed by these drugs. The present findings show that only a few non‐selective NSAIDs possess Aβ‐lowering properties and therefore have a profile potentially relevant to their clinical use in AD.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Alzheimer's disease and Down's syndrome: Sharing of a unique cerebrovascular amyloid fibril protein
Glenner, G. G., & Wong, C. W. (1984) · Biochemical and Biophysical Research Communications · doi:10.1016/0006-291x(84)91209-9 · Cited by 1,693
A subset of NSAIDs lower amyloidogenic Aβ42 independently of cyclooxygenase activity
Weggen, S., Eriksen, J. L., Das, P., Sagi, S. A., Wang, R., Pietrzik, C. U., Findlay, K. A., Smith, T. E., Murphy, M. P., Bulter, T., et al. (2001) · Nature · doi:10.1038/35102591 · Cited by 1,388 · cited 13×
“In the Tg2576 mouse model, high doses of NSAIDs are required to lower Ab levels in the brain of (i.e. 25–50 mg/kg/die; Weggen et al. 2001; Eriksen et al. 2003).”
BackgroundMethodResultInfluentialMcGeer, P. L., Schulzer, M., & McGeer, E. G. (1996) · Neurology · doi:10.1212/wnl.47.2.425 · Cited by 1,367 · cited 2×
“Several epidemiological studies (McGeer et al. 1996; In’t Veld et al. 2001; Lindsay et al. 2002; Zandi et al. 2002; Etminan et al. 2003) indicate that NSAIDs use reduces the risk of developing AD, slows the progression and decreases the severity of dementia.”
BackgroundDeMattos, R. B., Bales, K. R., Cummins, D. J., Dodart, J.-C., Paul, S. M., & Holtzman, D. M. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.151261398 · Cited by 1,298 · cited 1×
“Alternatively, NSAIDs could also act by facilitating the efflux of Ab from the brain to the bloodstream through mechanisms similar to those proposed for Ab vaccination (i.e. ‘peripheral sink’ hypothesis; DeMattos et al. 2001, 2002) or insulin-like growth factor-1 (Carro et al. 2002).”
BackgroundLindsay, J. (2002) · American Journal of Epidemiology · doi:10.1093/aje/kwf074 · Cited by 1,261 · cited 2×
“Several epidemiological studies (McGeer et al. 1996; In’t Veld et al. 2001; Lindsay et al. 2002; Zandi et al. 2002; Etminan et al. 2003) indicate that NSAIDs use reduces the risk of developing AD, slows the progression and decreases the severity of dementia.”
BackgroundNonsteroidal Antiinflammatory Drugs and the Risk of Alzheimer's Disease
in 't Veld, B. A., Ruitenberg, A., Hofman, A., Launer, L. J., van Duijn, C. M., Stijnen, T., Breteler, M. M. B., & Stricker, B. H. C. (2001) · New England Journal of Medicine · doi:10.1056/nejmoa010178 · Cited by 1,196 · cited 3×
“Several epidemiological studies (McGeer et al. 1996; In’t Veld et al. 2001; Lindsay et al. 2002; Zandi et al. 2002; Etminan et al. 2003) indicate that NSAIDs use reduces the risk of developing AD, slows the progression and decreases the severity of dementia.”
BackgroundRisk of Alzheimer's disease and duration of NSAID use
Stewart, W. F., Kawas, C., Corrada, M., & Metter, E. J. (1997) · Neurology · doi:10.1212/wnl.48.3.626 · Cited by 1,132 · cited 1×
“It has been reported that the risk of AD diminishes as the length of NSAIDs usage increases (Breitner et al. 1994; Stewart et al. 1997; Anthony et al. 2000; In’t Veld et al. 2001; Lindsay et al. 2002), and the onset of dementia is delayed in patients taking NSAIDs (Breitner et al. 1995).”
BackgroundNSAIDs and enantiomers of flurbiprofen target γ-secretase and lower Aβ42 in vivo
Eriksen, J. L., Sagi, S. A., Smith, T. E., Weggen, S., Das, P., McLendon, D. C., Ozols, V. V., Jessing, K. W., Zavitz, K. H., Koo, E. H., et al. (2003) · Journal of Clinical Investigation · doi:10.1172/jci18162 · Cited by 634
DeMattos, R. B., Bales, K. R., Cummins, D. J., Paul, S. M., & Holtzman, D. M. (2002) · Science · doi:10.1126/science.1067568 · Cited by 563
γ-Secretase, notch, Aβ and alzheimer's disease: Where do the presenilins fit in?
Sisodia, S. S., & St George-Hyslop, P. H. (2002) · Nature Reviews Neuroscience · doi:10.1038/nrn785 · Cited by 512
Etminan, M., Gill, S., & Samii, A. (2003) · BMJ · doi:10.1136/bmj.327.7407.128 · Cited by 511
Nonsteroidal anti-inflammatory drugs in Alzheimer's disease
Rich, J. B., Rasmusson, D. X., Folstein, M. F., Carson, K. A., Kawas, C., & Brandt, J. (1995) · Neurology · doi:10.1212/wnl.45.1.51 · Cited by 446
Nonsteroidal anti-inflammatory drug use and Alzheimer-type pathology in aging
Mackenzie, I. R. A., & Munoz, D. G. (1998) · Neurology · doi:10.1212/wnl.50.4.986 · Cited by 244
Effect of Anti-inflammatory Medications on Neuropathological Findings in Alzheimer Disease
Halliday, G. M., Shepherd, C. E., McCann, H., Reid, W. G. J., Grayson, D. A., Broe, G. A., & Kril, J. J. (2000) · Archives of Neurology · doi:10.1001/archneur.57.6.831 · Cited by 72
Aisen, P. S., Schafer, K. A., Grundman, M., Pfeiffer, E., Sano, M., Davis, K. L., Farlow, M. R., Jin, S., Thomas, R. G., Thal, L. J., et al. (2003) · JAMA · doi:10.1001/jama.289.21.2819 · Cited by 5
Cited by
Yang, F., Lim, G. P., Begum, A. N., Ubeda, O. J., Simmons, M. R., Ambegaokar, S. S., Chen, P. P., Kayed, R., Glabe, C. G., Frautschy, S. A., et al. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m404751200 · Cited by 2,336
Wyss-Coray (2006) · doi:10.1038/nm1484 · Cited by 1,284
Lee, J. W., Lee, Y. K., Yuk, D. Y., Choi, D. Y., Ban, S. B., Oh, K. W., & Hong, J. T. (2008) · Journal of Neuroinflammation · doi:10.1186/1742-2094-5-37 · Cited by 772
The role of amyloid β peptide 42 in Alzheimer's disease
Findeis, M. A. (2007) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2007.06.006 · Cited by 324
γ-Secretase inhibitors and modulators
Golde, T. E., Koo, E. H., Felsenstein, K. M., Osborne, B. A., & Miele, L. (2013) · Biochimica et Biophysica Acta (BBA) - Biomembranes · doi:10.1016/j.bbamem.2013.06.005 · Cited by 272
Metadata
- Authors
- Gasparini, L., Rusconi, L., Xu, H., Del Soldato, P., & Ongini, E.
- Venue
- Journal of Neurochemistry
- Publisher
- Wiley
- Published
- 2003-12-23
- Volume
- 88
- Issue
- 2
- Pages
- 337-348
- ISSN
- 0022-3042 (ISSN-L)
- 1471-4159
- OpenAlex
- W1551964881
- Cited by
- 98
- References
- 15
- FWCI
- 5.43
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.